Journal Watch · Journal of Medicinal Chemistry · 2026

Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells.

These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.

Prochazkova J, Carbain B, Marini V et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.5c02096PMID: 41740057Study type: in-vitro / cell study

TL;DR

These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.

Key findings

  • Both compounds effectively inhibit MUS81 in vitro and in cells, sensitizing cancer cells to DNA-damaging agents by impairing DNA repair.
  • These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.

What they did

Aberrant MUS81 activity causes DNA damage, chromosomal abnormalities, and genome instability, contributing to oncogenesis. Thus, pharmacological targeting of MUS81 is an attractive yet underexplored therapeutic strategy. We describe the discovery of two chemically distinct small-molecule classes of MUS81 inhibitors, exemplified by compounds MU262 and MU876.

Full abstract (original)

Background: Nucleases are promising pharmacological targets due to their essential role in maintaining genomic stability. They are crucial for regulation of cell viability, and their modulation is exploitable in disease prevention and treatment, including cancer. The conserved structure-specific endonuclease MUS81 resolves branched DNA intermediates during replication, repair, and recombination.

What they did: Aberrant MUS81 activity causes DNA damage, chromosomal abnormalities, and genome instability, contributing to oncogenesis. Thus, pharmacological targeting of MUS81 is an attractive yet underexplored therapeutic strategy. We describe the discovery of two chemically distinct small-molecule classes of MUS81 inhibitors, exemplified by compounds MU262 and MU876.

Results & conclusions: Both compounds effectively inhibit MUS81 in vitro and in cells, sensitizing cancer cells to DNA-damaging agents by impairing DNA repair. These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02096 · PubMed 41740057.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.

What type of study is this?

It is a in-vitro / cell study, published in Journal of Medicinal Chemistry in 2026. Aberrant MUS81 activity causes DNA damage, chromosomal abnormalities, and genome instability, contributing to oncogenesis.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02096. PubMed ID: 41740057. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Prochazkova J, Carbain B, Marini V et al.. Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c02096.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/discovery-of-two-structurally-distinct-classes-of-inhibitors-targeting-t-c02096/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides